MVA 85A
Alternative Names: AERAS-485; MVA-85A; MVA-85A-IMX-313; Tuberculosis subunit vaccine - Emergent BioSolutions/University of Oxford; Tuberculosis vaccine - University of OxfordLatest Information Update: 02 Oct 2021
Price :
$50 *
At a glance
- Originator University of Oxford
- Developer Aeras; University of Oxford
- Class Tuberculosis vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Tuberculosis
Most Recent Events
- 28 Sep 2018 No recent reports of development identified for phase-I development in Tuberculosis(Prevention, In volunteers) in United Kingdom (IM, Injection)
- 28 Sep 2018 No recent reports of development identified for phase-I development in Tuberculosis(Prevention, In volunteers) in United Kingdom (Inhalation, Aerosol)
- 21 Aug 2015 The University of Oxford plans a phase I trial for Tuberculosis in the United Kingdom (UKCRN19306)